These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 24145678

  • 1. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
    Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
    [Abstract] [Full Text] [Related]

  • 3. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [Abstract] [Full Text] [Related]

  • 4. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.
    Reinisch W, Altorjay I, Zsigmond F, Primas C, Vogelsang H, Novacek G, Reinisch S, Thomsen LL.
    Scand J Gastroenterol; 2015 Apr; 50(10):1226-33. PubMed ID: 25900645
    [Abstract] [Full Text] [Related]

  • 5. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Dahlerup JF, Jacobsen BA, van der Woude J, Bark LÅ, Thomsen LL, Lindgren S.
    Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
    [Abstract] [Full Text] [Related]

  • 6. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW.
    Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M.
    Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Stein J, Walper A, Klemm W, Farrag K, Aksan A, Dignass A.
    Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
    [Abstract] [Full Text] [Related]

  • 9. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI.
    Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
    [Abstract] [Full Text] [Related]

  • 10. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF, Muduma G.
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [Abstract] [Full Text] [Related]

  • 11. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J.
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):111-120. PubMed ID: 32049331
    [Abstract] [Full Text] [Related]

  • 13. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR.
    Arzneimittelforschung; 2010 Apr 04; 60(6a):386-98. PubMed ID: 20648930
    [Abstract] [Full Text] [Related]

  • 15. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
    Lichtenstein GR, Onken JE.
    Dig Dis Sci; 2018 Nov 04; 63(11):3009-3019. PubMed ID: 30056562
    [Abstract] [Full Text] [Related]

  • 16. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO).
    Mikhail AI, Schön S, Simon S, Brown C, Hegbrant JBA, Jensen G, Moore J, Lundberg LDI.
    BMC Nephrol; 2019 Jan 10; 20(1):13. PubMed ID: 30630452
    [Abstract] [Full Text] [Related]

  • 17. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
    Biggar P, Leistikow F, Walper A.
    Clin Nephrol; 2016 Dec 10; 86 (2016)(12):310-318. PubMed ID: 27737531
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010 Dec 10; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 19. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H.
    JAMA; 2020 Feb 04; 323(5):432-443. PubMed ID: 32016310
    [Abstract] [Full Text] [Related]

  • 20. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep 04; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.